Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

243
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
243
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

387
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
387
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

699
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
699
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

392
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
392
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

641
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
641

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic-Dysfunction Associated Steatotic Liver Disease.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations.

Alimentary pharmacology & therapeutics·2026
Same author

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Alimentary pharmacology & therapeutics·2026
Same author

Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'.

Nature reviews. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Dec 28, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.3K

New treatments/targets for primary biliary cholangitis.

Christophe Corpechot1, Raoul Poupon1, Olivier Chazouillères1

  • 1Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Hepatology Department, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris (APHP); INSERM UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.

JHEP Reports : Innovation in Hepatology
|February 11, 2020
PubMed
Summary

Primary biliary cholangitis (PBC) is a chronic liver disease. This review covers current and emerging treatments for PBC, offering clinicians insights into managing this autoimmune condition.

Keywords:
FXRPBCPPARcholestasisfibratesinflammationliver diseaseobeticholic acidursodeoxycholic acid

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.1K

Related Experiment Videos

Last Updated: Dec 28, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.3K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.1K

Area of Science:

  • Hepatology
  • Autoimmune diseases
  • Cholestatic liver disease

Background:

  • Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease.
  • Ursodeoxycholic acid is the current standard of care.
  • Untreated PBC can lead to cirrhosis and liver failure.

Purpose of the Study:

  • To provide clinicians with an overview of current treatment options for PBC.
  • To discuss recent advances in second-line therapies for PBC.
  • To highlight future therapeutic developments in PBC management.

Main Methods:

  • Literature review of current and emerging PBC treatments.
  • Analysis of clinical trial data for second-line therapies.
  • Synthesis of expert opinion on future directions in PBC care.

Main Results:

  • Ursodeoxycholic acid remains the first-line therapy for PBC.
  • Several new agents show promise as second-line treatments.
  • Ongoing research is exploring novel therapeutic targets for PBC.

Conclusions:

  • Optimizing PBC management requires a comprehensive understanding of available and emerging treatments.
  • Second-line therapies are crucial for patients not responding adequately to ursodeoxycholic acid.
  • Future research holds promise for improved outcomes in PBC patients.